Condition
Recurrent WHO Grade 3 Glioma
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (2)
P 2 (1)
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT06964737Phase 1Recruiting
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
NCT06410248Phase 1Recruiting
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
NCT05859334Phase 2Recruiting
Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Showing all 3 trials